Velligan Dawn I, Fredrick Megan, Mintz Jim, Li Xueying, Rubin Maureen, Dube Sanjay, Deshpande Smita N, Trivedi Jitendra K, Gautam Shiv, Avasthi Ajit, Kern Robert S, Marder Stephen R
Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX;
Department of Social Work, University of Texas at San Antonio, San Antonio, TX;
Schizophr Bull. 2014 Sep;40(5):1047-52. doi: 10.1093/schbul/sbt148. Epub 2013 Nov 9.
The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was designed to encourage the development of cognitive enhancing agents for schizophrenia. For a medication to receive this indication, regulatory agencies require evidence of improvement in both cognition and functional outcome. Functional capacity measures typically used in clinical trials as intermediate measures of functional outcome must be adapted to fit different cultural contexts for use internationally. We examined the psychometric properties of the MATRICS Functional Assessment Battery (MFAB), comprised of 2 subtests from the UCSD Performance-based Skills Assessment (UPSA) and one from the Test of Adaptive Behavior in Schizophrenia (TABS) that were rated by experts in a previous study to be the most appropriate functional capacity assessments across different cultural contexts.
Four sites in India administered the MFAB, a brief version of the UPSA, the MATRICS Cognitive Consensus Battery, measures of symptomatology, and a measure of global functional outcome to 141 individuals with schizophrenia at a baseline assessment and at 4 weeks later.
Test-retest reliability based on the intraclass correlation coefficient was significantly better for the UCSD Performance-Based Skills Assessment-Brief (UPSA-B). Pearson correlation coefficients over time were not significantly different for the 2 measures. Only the MFAB was significantly correlated with functional outcome as measured by the Specific Levels of Functioning Scale.
The psychometric properties of the MFAB and UPSA-B were similar. The MATRICS scientific board chose to translate the MFAB into multiple languages for potential use in studies of novel medications seeking an indication for improving cognition in schizophrenia.
精神分裂症认知改善测量与治疗研究(MATRICS)计划旨在鼓励开发用于精神分裂症的认知增强药物。对于一种药物要获得该适应症,监管机构要求有认知和功能结局改善的证据。临床试验中通常用作功能结局中间指标的功能能力测量方法必须加以调整,以适应不同文化背景以便在国际上使用。我们检验了MATRICS功能评估量表(MFAB)的心理测量特性,该量表由加利福尼亚大学圣地亚哥分校基于表现的技能评估(UPSA)中的2个分测验和精神分裂症适应行为测验(TABS)中的1个分测验组成,在之前的一项研究中,专家们认为这些分测验是不同文化背景下最合适的功能能力评估方法。
印度的4个研究点在基线评估时和4周后,对141名精神分裂症患者施测了MFAB、UPSA的简短版本、MATRICS认知共识量表、症状学测量方法以及整体功能结局测量方法。
基于组内相关系数的重测信度,加利福尼亚大学圣地亚哥分校基于表现的技能评估简短版(UPSA-B)明显更好。两种测量方法随时间的皮尔逊相关系数没有显著差异。只有MFAB与功能水平特定量表所测量的功能结局显著相关。
MFAB和UPSA-B的心理测量特性相似。MATRICS科学委员会选择将MFAB翻译成多种语言,以便在寻求改善精神分裂症认知适应症的新型药物研究中可能使用。